Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis

Leuk Lymphoma. 2016 May;57(5):1211-4. doi: 10.3109/10428194.2015.1079319. Epub 2015 Oct 12.

Authors

Erman Öztürk¹, Murat Özbalak², Selin Berk², Işıl Erdoğan², Emin Avşar³, Anıl Dolgun⁴, Mustafa Çetiner¹, Nil Molinas Mandel⁵, Fevzi Fırat Yalnız², Tuğrul Elverdi², Ayşe Salihoğlu², Ahmet Emre Eşkazan², Muhlis Cem Ar², Şeniz Öngören², Zafer Başlar², Yıldız Aydın², Teoman Soysal², Burhan Ferhanoğlu¹

Affiliations

¹ a Division of Hematology, Department of Internal Medicine , Koç University, School of Medicine , Istanbul .
² b Division of Hematology, Department of Internal Medicine , Istanbul University, Cerrahpasa Medical Faculty , Istanbul .
³ c Division of Oncology , V.K.V. American Hospital , Istanbul .
⁴ d Department of Biostatstics , Hacettepe University , Ankara , and.
⁵ e Division of Oncology, Department of Internal Medicine , Koç University, School of Medicine , Istanbul , Turkey.

PMID: 26294270
DOI: 10.3109/10428194.2015.1079319

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Humans
Kaplan-Meier Estimate
Lymphoma, Large B-Cell, Diffuse / diagnosis
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / mortality*
Prednisone / therapeutic use
Prognosis
ROC Curve
Retrospective Studies
Rituximab
Vincristine / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
Biomarkers, Tumor
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone